Dutch MEB plans to spread EMA workload after Brexit to offset loss of the MHRA

Dutch regulators are looking to spread European Medicines Agency (EMA) work which is currently handled by the United Kingdom (UK) across multiple agencies after Brexit. The Dutch Medicines Evaluation Board’s (MEB) aim is to involve more member states in EMA’s activities, rather than significantly increasing its own capacity.

Currently the EMA relies heavily on the Medicines and Healthcare products Regulatory Agency (MHRA) but looks set to lose access to this capacity when the UK leaves the European Union (EU). In anticipation of increased workload, the MEB enlarged its capacity last year by using temporary financial support from the Dutch government. However, rather than growing to take on all of the MHRA’s work, the MEB wants to equip other member states to take off some of the burden.

Hiring drives by regulatory agencies in countries such as Denmark and Spain could result in the EMA having a broader pool of talent to draw upon after Brexit than in the past. The MEB is currently working to enhance the pool by helping agencies from smaller countries that joined the EU more recently to build up their regulatory capacity. 10 member states have already signed up to receive MEB’s support. The MEB hopes that these agencies will take on some of the work currently handled by the MHRA.

To view the MEB annual report 2017, please click here.